Session

Overview: The main aim of radiotherapy in H&N is to achieve tumor control with minimal normal tissue toxicity. This symposium addresses the issue of toxicity from a different perspectives: tumour biologic exploration of the heterogeneity of radiosensitivity in H&N – biomarkers as classifiers?; the use of Comprehensive Toxicity Risk Profiles in identification of the most relevant toxicity and thereby organ at risk to spare for the individual patient; novel radiotherapy/drug treatment combinations’ effect on the toxicity profile; 10 years of experience in reducing radiation-induced toxicity by reducing the irradiated volume.